Skip to main content Accessibility help
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 1
  • Cited by
    This chapter has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Lubman, Dan I. King, Joel A. and Castle, David J. 2010. Treating comorbid substance use disorders in schizophrenia. International Review of Psychiatry, Vol. 22, Issue. 2, p. 191.

  • Print publication year: 2009
  • Online publication date: August 2009

14 - Substance misuse in first-episode psychosis

from Section 6 - The critical period: other psychopathology and comorbidity
Recommend this book

Email your librarian or administrator to recommend adding this book to your organisation's collection.

The Recognition and Management of Early Psychosis
  • Online ISBN: 9780511576287
  • Book DOI:
Please enter your name
Please enter a valid email address
Who would you like to send this to *


Addington, J. & Addington, D. (2001). Impact of an early psychosis programme on substance use. Psychiatric Rehabilitation Journal, 25, 60–7.
Andreasson, S., Allebeck, P., Engstrom, A. & Rydberg, U. (1987). Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet, ü, 1483–6.
Arndt, S., Tyrrell, G., Flaum, M. & Andreasen, N. C. (1992). Comorbidity of substance abuse and schizophrenia: the role of premorbid adjustment. Psychological Medicine, 22, 379–88.
Arendt, M., Rosenberg, R., Foldager, L., Perto, G. & Munk-Jorgensen, P. (2005). Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases. British Journal of Psychiatry, 187, 510–15.
Arseneault, L., Cannon, M., Poulton, R. et al. (2002). Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. British Medical Journal, 325, 1212–13.
Arseneault, L., Cannon, M., Witton, J. & Murray, R. M. (2004). Causal association between cannabis and psychosis: examination of the evidence. British Journal of Psychiatry, 184, 110–17.
Baker, A., Lewin, T., Reichler, H. et al. (2002). Motivational interviewing among psychiatric in-patients with substance use disorders. Acta Psychiatrica Scandinavica, 106, 233–40.
Baker, A., Bucci, S. & Kay-Lambkin, F. (2004). Intervention for Alcohol, Cannabis and Amphetamine Use among People with a Psychotic Illness. [NDARC Technical Report No. 193.] Sydney: National Drug and Alcohol Research Centre.
Baker, A., Bucci, S., Lewin, T. J. et al. (2006a). Cognitive-behavioural therapy for substance use disorders in people with psychotic disorders: randomised controlled trial. British Journal of Psychiatry, 188, 439–48.
Baker, A., Richmond, R., Haile, M. et al. (2006b). Randomised controlled trial of a smoking cessation intervention among people with a psychotic disorder. American Journal of Psychiatry, 163, 1934–42.
Barrowclough, C., Haddock, G., Tarrier, N. et al. (2001) Randomized controlled trial of motivational interviewing, cognitive behaviour therapy, and family intervention for patients with comorbid schizophrenia and substance use disorders. American Journal of Psychiatry, 158, 1706–13.
Blanchard, J. J., Squires, D., Henry, T. et al. (1999). Examining an affect regulation model of substance abuse in schizophrenia: the role of traits and coping. Journal of Nervous and Mental Disease, 187, 72–9.
Blanchard, J. J., Brown, S. A., Horan, W. P. & Sherwood, A. R. (2000). Substance use disorders in schizophrenia: review, integration, and a proposed model. Clinical Psychology Review, 20, 207–34.
Brown, S., Barraclough, B. & Inskip, H. (2000). Causes of the excess mortality of schizophrenia. British Journal of Psychiatry, 177, 212–17.
Cantwell, R., Brewin, J., Glazebrook, C. et al. (1999). Prevalence of substance misuse in first-episode psychosis. British Journal of Psychiatry, 174, 150–3.
Caspi, A., Moffitt, T. E., Cannon, M. et al. (2005). Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene x environment interaction. Biological Psychiatry, 57, 1117–27.
Chambers, R. A., Krystal, J. H. & Self, D. W. (2001). A neurobiological basis for substance abuse comorbidity in schizophrenia. Biological Psychiatry, 50, 71–83.
Coldham, E. L., Addington, J. & Addington, D. (2002). Medication adherence of individuals with a first episode of psychosis. Acta Psychiatrica Scandinavica, 106, 286–90.
Degenhardt, L. & Hall, W. (2001). The association between psychosis and problematical drug use among Australian adults: findings from the National Survey of Mental Health and Well-being. Psychological Medicine, 31, 659–68.
Degenhardt, L., Hall, W. & Lynskey, M. (2003). Testing hypotheses about the relationship between cannabis use and psychosis. Drug and Alcohol Dependence, 71, 37–48.
DeLisi, L. E., Boccio, A. M., Riordan, H. et al. (1991). Familial thyroid disease and delayed language development in first admission patients with schizophrenia. Psychiatry Research, 38, 39–50.
Dervaux, A., Bayle, F. J., Laqueille, X. et al. (2001). Is substance abuse in schizophrenia related to impulsivity, sensation seeking, or anhedonia? American Journal of Psychiatry, 158, 492–4.
Dixon, L., Haas, G., Weiden, P. J., Sweeney, J. & Frances, A. J. (1991). Drug abuse in schizophrenic patients: clinical correlates and reasons for use. American Journal of Psychiatry, 148, 224–30.
Drake, R. E., Mueser, K. T., Brunette, M. F. & McHugo, G. J. (2004). A review of treatments for people with severe mental illnesses and co-occurring substance use disorders. Psychiatric Rehabilitation Journal, 27, 360–74.
Edwards, J., Hinton, M., Elkins, K. & Athanasopoulos, O. (2003). Cannabis and first-episode psychosis: the CAP project. In H. L. Graham, A. Copello, M. J. Birchwood & K. T. Mueser (eds.), Substance Misuse in Psychosis: Approaches to Treatment and Service Delivery. Chichester, UK: John Wiley, pp. 283–304.
Edwards, J., Elkins, K., Hinton, M. et al. (2006). Randomized controlled trial of a cannabis-focused intervention for young people with first-episode psychosis. Acta Psychiatrica Scandinavica, 114, 109–17.
Evins, A. E., Mays, V. K., Rigotti, N. A. et al. (2001). A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia. Nicotine and Tobacco Research, 3, 397–403.
Fergusson, D. M., Horwood, L. J. & Swain-Campbell, N. R. (2003). Cannabis dependence and psychotic symptoms in young people. Psychological Medicine, 33, 15–21.
George, T. P., Ziedonis, D. M., Feingold, A. et al. (2000). Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. American Journal of Psychiatry, 157, 1835–42.
George, T. P., Vessicchio, J. C., Termine, A. et al. (2002). A placebo controlled trial of bupropion for smoking cessation in schizophrenia. Biological Psychiatry, 52, 53–61.
Gleeson, J, Jackson, H. J., Stavely, H. & Burnett, P. (1999). Family intervention in early psychosis. In P. D. McGorry & H. J. Jackson (eds.), The Recognition and Management of Early Psychosis. Cambridge, UK: Cambridge University Press, pp. 376–406.
Graham, H. L., Copello, A., Birchwood, M. J. et al. (2004). Cognitive-behavioural Integrated Treatment (C-BIT): A Treatment Manual for Substance Misuse in People with Severe Mental Health Problems. Chichester, UK: John Wiley.
Green, B., Kavanagh, D. & Young, R. M. (2004). Reasons for cannabis use in men with and without psychosis. Drug and Alcohol Review, 23, 445–53.
Gut-Fayand, A., Dervaux, A., Olie, J. et al. (2001). Substance abuse and suicidality in schizophrenia: a common risk factor linked to impulsivity. Psychiatry Research, 102, 65–72.
Haddock, G., Barrowclough, C., Tarrier, N. et al. (2003). Cognitive-behavioural therapy and motivational intervention for schizophrenia and substance misuse: 18-month outcomes of a randomised controlled trial. British Journal of Psychiatry, 183, 418–26.
Hambrecht, M. & Häfner, H. (1996). Substance abuse and the onset of schizophrenia. Biological Psychiatry, 40, 1155–63.
Hambrecht, M. & Häfner, H. (1998). Are symptoms observed differently in male and female first-episode patients? Schizophrenia Research, 29, 186.
Hamera, E., Schneider, J. K. & Deviney, S. (1995). Alcohol, cannabis, nicotine, and caffeine use and symptom distress in schizophrenia. Journal of Nervous and Mental Disease, 183, 559–65.
Henquet, C., Murray, R., Linszen, D. & van Os, J. (2005). The environment and schizophrenia: the role of cannabis use. Schizophrenia Bulletin, 31, 608–12.
Hercus, M., Lubman, D. I. & Hellard, M. (2005). Blood borne viral and sexually transmissible infections among psychiatric populations: what are we doing about them? Australian and New Zealand Journal of Psychiatry, 39, 849–55.
Hides, L., Lubman, D. & Dawe, S. (2004). Models of co-occurring substance misuse and psychosis: are personality traits the missing link? Drug and Alcohol Review, 23, 425–32.
Hides, L., Dawe, S., Kavanagh, D. J. & Young, R. M. (2006). Psychotic symptom and cannabis relapse in recent-onset psychosis: a prospective study. British Journal of Psychiatry, 189, 137–43.
Hinton, M., Elkins, K., Edwards, J. & Donovan, K. (2002). Cannabis and Psychosis: An Early Psychosis Treatment Manual. Melbourne: Early Psychosis Prevention and Intervention Centre.
James, W., Preston, N. J., Koh, G. et al. (2004). A group intervention which assists patients with dual diagnosis reduce their drug use: a randomized controlled trial. Psychological Medicine, 34, 983–90.
Jeffery, D. P., Ley, A., McLaren, S. & Siegfried N. (2000). Psychosocial treatment programmes for people with both severe mental illness and substance misuse. Cochrane Database of Systematic Reviews, 2, CD001088. [DOI: 10.1002/14651858.CD001088].
Kavanagh, D. J., Mueser, K. T. & Baker, A. (2003a). Management of comorbidity. In M. Teesson & H. Proudfoot (eds.), Comorbid Mental Disorders and Substance Use Disorders: Epidemiology, Prevention and Treatment. Canberra: Commonwealth of Australia, pp. 78–120.
Kavanagh, D. J., Young, R., White, A. et al. (2003b). Start over and survive: a brief intervention for substance misuse in early psychosis. In H. L. Graham, A. Copello, M. J. Birchwood & K. T. Mueser (eds.), Substance Misuse in Psychosis: Approaches to Treatment and Service Delivery. Chichester, UK: John Wiley, pp. 244–58.
Kavanagh, D. J., Young, R., White, A. et al. (2004). A brief motivational intervention for substance misuse in recent-onset psychosis. Drug and Alcohol Review, 23, 151–5.
Kay-Lambkin, F. J., Baker, A. L. & Lewin, T. J. (2004). The ‘co-morbidity roundabout’: a framework to guide assessment and intervention strategies and engineer change among people with comorbid problems. Drug and Alcohol Review, 23, 407–23.
Kemp, R., Kirov, G., Everitt, B., Hayward, P. & David, A. (1998). Randomised controlled trial of compliance therapy: 18-month follow-up. British Journal of Psychiatry, 172, 413–19.
Khantzian, E. (1985). The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence. American Journal of Psychiatry, 142, 1259–64.
Lachman, H. M., Papolos, D. F., Saito, T. et al. (1996). Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics, 6, 243–50.
Lambert, M., Conus, P., Lubman, D. I. et al. (2005). The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis. Acta Psychiatrica Scandinavica, 112, 141–8.
Lewis, S. W., Tarrier, N. & Drake, R. J. (2005). Integrating non-drug treatments in early schizophrenia. British Journal of Psychiatry, 187, 65–71.
Linszen, D. H., Dingemans, P. M. & Lenior, M. E. (1994). Cannabis abuse and the course of recent-onset schizophrenic disorders. Archives of General Psychiatry, 51, 273–9.
Liraud, F. & Verdoux, H. (2000). Which temperamental characteristics are associated with substance use in subjects with psychotic and mood disorders? Psychiatry Research, 93, 63–72.
Martino, S., Carroll, K. M., O’Malley, S. S. & Rounsaville, B. J. (2000). Motivational interviewing with psychiatrically ill substance abusing patients. American Journal on Addictions, 9, 88–91.
McGorry, P. D. (1995). Psychoeducation in first-episode psychosis: a therapeutic process. Psychiatry, 58, 313–28.
McGorry, P., Killackey, E., Elkins, K., Lambert, M. & Lambert, T. (2003). Summary: Australian and New Zealand clinical practice guideline for the treatment of schizophrenia. Australasian Psychiatry, 11, 136–47.
McHugo, G. J., Drake, R. E., Burton, H. L. & Ackerson, T. H. (1995). A scale for assessing the stage of substance abuse treatment in persons with severe mental illness. Journal of Nervous and Mental Disease, 182, 164–7.
Miller, W. & Rollnick, S. (2002). Motivational Interviewing: Preparing People for Change. New York: Guilford Press.
Mueser, K. T. & Drake, R. E. (2003). Integrated dual disorder treatment in New Hampshire (USA). In H. L. Graham, A. Copello, M. J. Birchwood & K. T. Mueser (eds.), Substance Misuse in Psychosis: Approaches to Treatment and Service Delivery. Chichester, UK: John Wiley, pp. 93–105.
Mueser, K. T., Drake, R. E. & Wallach, M. A. (1998). Dual diagnosis: a review of aetiological theories. Addictive Behaviours, 23, 717–34.
Mueser, K. T., Rosenberg, S. D., Drake, R. E. et al. (1999). Conduct disorder, antisocial personality disorder and substance use disorders in schizophrenia and major affective disorders. Journal of Studies on Alcohol, 60, 278–84.
Nordentoft, M., Jeppesen, P., Abel, M. et al. (2002). OPUS study: suicidal behaviour, suicidal ideation and hopelessness among patients with first-episode psychosis – one-year follow-up of a randomised controlled trial. British Journal of Psychiatry, 181, 98–106.
Norman, R. M. G. & Malla, A. K. (2002). Examining adherence to medication and substance use as possible confounds of duration of untreated psychosis. Journal of Nervous and Mental Disease, 190, 331–4.
Osher, F. C. & Kofoed, L. L. (1989). Treatment of patients with psychiatric and psychoactive substance use disorders. Hospital and Community Psychiatry, 40, 1025–30.
Rabinowitz, J., Bromet, E. J., Carlson, L. G., Kovasznay, B. & Schwartz, J. E. (1998). Prevalence and severity of substance use disorders and onset of psychosis in first-admission psychotic patients. Psychological Medicine, 28, 1411–19.
Regier, D. A., Farmer, M. E., Rae, D. S. et al. (1990). Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) study. Journal of the American Medical Association, 264, 2511–18.
Robinson, D., Woerner, M. G., Alvir, J. M. J. et al. (1999). Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Archives of General Psychiatry, 56, 241–7.
Rollnick, S., Heather, N., Gold, R. & Hall, W. (1992). Development of a short ‘readiness to change’ questionnaire for use in brief, opportunistic interventions among excessive drinkers. British Journal of Addiction, 87, 743–54.
Rosenberg, S. D., Drake, R., Wolford, G. L. et al. (1998). Dartmouth Assessment of Lifestyle Instrument (DALI): a substance use disorder screen for people with severe mental illness. American Journal of Psychiatry, 155, 232–8.
Saunders, J. B., Aasland, O. G., Babor, T. F., de le Fuente, J. R. & Grant, M. (1993). Development of the alcohol use disorders identification test (AUDIT). WHO collaborative project on early detection of persons with harmful alcohol consumption. Addiction, 88, 791–804.
Semple, D. M., McIntosh, A. M. & Lawrie, S. M. (2005). Cannabis as a risk factor for psychosis: systematic review. Journal of Psychopharmacology, 19, 187–94.
Sevy, S., Robinson, D. G., Holloway, S. et al. (2001). Correlates of substance misuse in patients with first-episode schizophrenia and schizoaffective disorder. Acta Psychiatrica Scandinavica, 104, 367–74.
Sorbara, F., Liraud, F., Assens, F., Abalan, F. & Verdoux, H. (2003). Substance use and the course of early psychosis: a 2-year follow-up of first-admitted subjects. European Psychiatry, 18, 133–6.
Spencer, C., Castle, D. & Michie, P. T. (2002). Motivations that maintain substance use among individuals with psychotic disorders. Schizophrenia Bulletin, 28, 233–47.
Strakowski, S. M., Keck, P. E., McElroy, S. L. et al. (1998). Twelve-month outcome after a first hospitalization for affective psychosis. Archives of General Psychiatry, 55, 49–55.
Swanson, A. J., Pantalon, M. V. & Cohen, K. R. (1999). Motivational interviewing and treatment adherence among psychiatric and dually diagnosed patients. Journal of Nervous and Mental Disease, 187, 630–5.
Van Mastrigt, S., Addington, J. & Addington, D. (2004). Substance misuse at presentation to an early psychosis program. Social Psychiatry and Psychiatric Epidemiology, 39, 69–72.
Verdoux, H., Liraud, F., Gonzales, B. et al. (2001). Predictors and outcome characteristics associated with suicidal behaviour in early psychosis: a two-year follow-up of first-admitted subjects. Acta Psychiatrica Scandinavica, 103, 347–54.
Verma, S. K., Subramaniam, M., Chong, S. A. & Kua, E. H. (2002). Substance abuse in schizophrenia: a Singapore perspective. Social Psychiatry and Psychiatric Epidemiology, 37, 326–8.
Voruganti, L. N. P., Slomka, P., Zabel, P., Mattar, A. & Awad, A. G. (2001). Cannabis induced dopamine release: an in-vivo SPECT study. Psychiatry Research Neuroimaging, 107, 173–7.
Wade, D., Harrigan, S., Edwards, J. et al. (2005). Patterns and predictors of substance use disorders and daily tobacco use in first-episode psychosis. Australian and New Zealand Journal of Psychiatry, 39, 892–8.
Wade, D., Harrigan, S., Edwards, J. et al. (2006a). Course of substance misuse and daily tobacco use in first-episode psychosis. Schizophrenia Research, 81, 145–50.
Wade, D., Harrigan, S., Edwards, J. et al. (2006b). Substance misuse in first-episode psychosis: 15-month prospective follow-up study. British Journal of Psychiatry, 189, 229–34.
WHO ASSIST Working Group (2002). The alcohol, smoking, and substance involvement screening test (ASSIST): development, reliability and feasibility. Addiction, 97, 1183–94.
Zammit, S., Allebeck, P., Andreasson, S., Lundberg, I. & Lewis, G. (2002). Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. British Medical Journal, 325, 1199–204.